

Lilly leaves investors itching for more details



[Madeleine Armstrong](#)

Lilly and Almirall's atopic dermatitis contender lebrikizumab has prevailed in its pivotal trials, Advocate 1 and 2. But, other than the groups saying "more than half" of patients achieved 75% skin clearance, or Easi-75, details were thin on the ground. Investors will have to wait for an undisclosed 2022 medical meeting to see [whether lebri has held its own in a cross-trial comparison against Sanofi and Regeneron's Dupixent](#). The signs are good: in Dupixent's pivotal trials, [51 and 44% of patients receiving the drug every other week met Easi-75](#) on a non-placebo-adjusted basis. It will also be important to see how lebri performed on its second co-primary endpoint, the proportion of patients with an IGA score of 0 or 1. Another factor is how different dosing regimens of lebri fared: patients received the drug every two or four weeks, potentially giving lebri a convenience advantage over Dupixent. Finally, safety will be on the agenda as it is hoped that lebri could sidestep the issue of conjunctivitis, which [occurred in 10% of patients in Dupixent's monotherapy trials](#). Lilly said today that conjunctivitis was one of the most common adverse events seen with lebri, so actual numbers will be keenly awaited.

Awaiting detailed data: what lebri needs to do in phase 3

Endpoint	Dupixent ph3*	Lebri ph2**
IGA 0 or 1	27-28 points	19-30 points
EASI-75	32-36 points	32-37 points
EASI-90	23-28 points	25-33 points

*Note: all values placebo-adjusted; *monotherapy ph3 trials (Solo-1 & Solo-2); **250mg every 4wks & 250mg every 2wks, all secondary endpoints. Source: Dupixent label & [JAMA Dermatology](#).*

Lebri's phase 3 trials

Study name/ID	Details	Data
Advocate 1, NCT04146363	Placebo-controlled, lebri monotherapy every 2/4 wks	Topline data released; positive
Advocate 2, NCT04178967	Placebo-controlled, lebri monotherapy every 2/4 wks	Topline data released; positive
Adhere, NCT04250337	Placebo-controlled, lebri + topical corticosteroids every 2 wks	Completes Aug 2021
Adore, NCT04250350	Adolescents, single-arm, lebri every 2 wks	Completes Apr 2022
Adjoin, NCT04392154	Long-term extension, lebri every 2/4 wks	Completes May 2024

Source: Evaluate Pharma & [clinicaltrials.gov](#).

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas

+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

© Copyright 2022 Evaluate Ltd.